^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunomodulator

    Related drugs:
    19h
    IVIG Vs SCIG in CIDP (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Rutgers, The State University of New Jersey | Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Dec 2025
    Enrollment closed • Trial completion date
    2d
    R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=33, Not yet recruiting, Rise Therapeutics LLC | Initiation date: Sep 2024 --> Mar 2025
    Trial initiation date
    2d
    CMP-001 for Relapsed and Refractory Lymphoma (clinicaltrials.gov)
    P1/2, N=39, Active, not recruiting, Umar Farooq | Suspended --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • vidutolimod (CMP-001)
    3d
    A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults (clinicaltrials.gov)
    P2, N=838, Recruiting, GlaxoSmithKline | Active, not recruiting --> Recruiting | N=510 --> 838 | Trial completion date: Dec 2024 --> Jun 2025
    Enrollment open • Enrollment change • Trial completion date
    3d
    URSTAR: Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance (clinicaltrials.gov)
    P=N/A, N=128, Not yet recruiting, First Affiliated Hospital Xi'an Jiaotong University
    New trial
    3d
    HOPE-2-OLE: Open-label Extension of the HOPE-2 Trial (clinicaltrials.gov)
    P2, N=13, Active, not recruiting, Capricor Inc. | Trial completion date: Mar 2025 --> Mar 2026
    Trial completion date
    5d
    Effectiveness and Safety of Prophylactic Antifungal Therapy in Liver Failure Patients Based on Risk Stratification (ChiCTR2400091203)
    P=N/A, N=339, Not yet recruiting, Shulan (Hangzhou) hospital; Shulan (Hangzhou) hospital
    New trial
    5d
    Clinical efficacy and economic evaluation of micafantine and voriconazole in the preemptive treatment of invasive pulmonary candidiasis (ChiCTR2400089285)
    P=N/A, N=100, Recruiting, People's Hospital of Leshan; People's Hospital of Leshan
    New trial • HEOR
    5d
    Efficacy and Safety of Hydroxychloroquine Combined with Doxycycline for Treatment of Patients With Rosacea:A Randomized, Double-blind, Double-dummy Clinical Trial (ChiCTR2400089784)
    P4, N=58, Completed, Guizhou Provincial People's Hospital (Single center research); Guizhou Provincial People's Hospital
    New P4 trial
    |
    hydroxychloroquine
    5d
    Helicobacter pylori eradication with minocycline-containing double/quadruple therapy：prospective, multicenter, open-label, randomized controlled clinical study (ChiCTR2400089850)
    P4, N=600, Recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P4 trial
    |
    minocycline
    7d
    Open-label Trial of IVIG in Children With PANS (clinicaltrials.gov)
    P2, N=10, Recruiting, Göteborg University | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
    Trial completion date • Trial primary completion date
    7d
    PolyTreg Immunotherapy in Islet Transplantation (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, University of Alberta | Trial completion date: Oct 2024 --> Jan 2025
    Trial completion date
    |
    Campath (alemtuzumab)
    7d
    A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer (clinicaltrials.gov)
    P2, N=77, Terminated, Regeneron Pharmaceuticals | Active, not recruiting --> Terminated; Sponsor Decision related to study drug supply
    Trial termination • Combination therapy • Metastases
    |
    Libtayo (cemiplimab-rwlc) • vidutolimod (CMP-001)
    7d
    Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. (clinicaltrials.gov)
    P1/2, N=13, Completed, Immunis, Inc. | Active, not recruiting --> Completed | Trial primary completion date: Nov 2024 --> Aug 2024
    Trial completion • Trial primary completion date
    9d
    Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Thymosin Α1) V (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Nanjing Medical University | N=100 --> 300 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Zadaxin (thymalfasin)
    9d
    Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=33, Recruiting, City of Hope Medical Center | Initiation date: Sep 2024 --> May 2024
    Trial initiation date
    |
    melphalan • fludarabine IV • thiotepa • Orca-T
    11d
    ACAT1 Induces the Differentiation of Glioblastoma Cells by Rewiring Choline Metabolism. (PubMed, Int J Biol Sci)
    Importantly, ACAT1 negatively regulated the choline metabolic pathway, which is crucial for the differentiation of GBM cells. Finally, we demonstrated that a naturally available substance, chlorogenic acid (CHA), could inhibit phosphorylation of ACAT1 and so delay GBM progression, CHA is a promising candidate to treat GBM because it could induce the differentiation of cancer cells.
    Journal
    |
    ACAT1 (Acetyl-CoA Acetyltransferase 1)
    |
    chlorogenic acid
    11d
    A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma (clinicaltrials.gov)
    P2, N=60, Suspended, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • vidutolimod (CMP-001)
    12d
    Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. (PubMed, Cancer Cell)
    Our findings support that combined vidutolimod and nivolumab stimulates a broad anti-tumor immune response and is associated with distinct baseline myeloid gene signature and gut microbiota. ClinicalTrials.gov identifier: NCT03618641.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Opdivo (nivolumab) • vidutolimod (CMP-001)
    14d
    Glatiramer Acetate Complexes CpG Oligodeoxynucleotides into Nanoparticles and Boosts Their TLR9-Driven Immunity. (PubMed, Mol Pharm)
    A subsequent in vivo experiment confirmed the achievement of potent tumor suppression while mitigating systemic immune-related toxicities. Together, these data help elucidate the noncanonical role of GA to serve as a nucleic acid delivery scaffold that can improve the efficacy and safety of CpG adjuvant for clinical cancer immunotherapy.
    Journal
    |
    TLR9 (Toll Like Receptor 9)
    14d
    NECESSITY: New Clinical End-points in Patients With Primary Sjögren's Syndrome (clinicaltrials.gov)
    P2, N=300, Recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Feb 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    hydroxychloroquine • leflunomide
    15d
    FILAXOS: A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov)
    P=N/A, N=900, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    15d
    The immunomodulator effect of Stevia rebaudiana Bertoni mediated by TNF-α and IL-1β in peripheral blood in diabetic rats. (PubMed, Food Sci Nutr)
    The amount of CD8 + T cells decreased significantly in the diabetes +25 mg/kg bW stevia group compared to the diabetes group (*p < .05). The stevia diet leads to a reduction in peripheral circulating cytotoxic T cells and proinflammatory cytokines interleukin-1 beta and tumor necrosis factor-alpha under hyperglycemic conditions.
    Preclinical • Journal • Immunomodulating
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL1B (Interleukin 1, beta)
    15d
    Potential protective role of chlorogenic acid against cyclophosphamide-induced reproductive damage in male mice. (PubMed, Toxicol Res (Camb))
    This mechanism may be correlated with the inhibition of oxidative stress and antioxidation levels. Therefore, CGA has a protective impact on testicular injuries arising from CP in mice.
    Preclinical • Journal
    |
    CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
    |
    cyclophosphamide • chlorogenic acid
    15d
    Phenolic Profile of Seedless Ziziphus mauritiana Fruits and Leaves Extracts with In Vivo Antioxidant and Anti-inflammatory Activities: Influence on Pro-Inflammatory Mediators. (PubMed, Chem Biodivers)
    Reverse Phase High Performance Liquid Chromatography analysis of SZM leaves and fruit extracts in ethanol revealed the presence of sixteen phenolics including chlorogenic acid, p-coumeric acid, gallic acid, kaempferol and rutin... The fruit extract exhibited inhibition (98.1%) at the dose of 500 mg/kg body weight (BW), comparable to the indomethacin (98.4%)...The leaf extract demonstrated the higher antioxidant potential as evident from the superoxide dismutase, catalase, malondialdehyde, glutathione peroxidase and glutathione levels. These findings suggest that SZM leaf and fruit extracts possess potential antioxidant and anti-inflammatory properties and can play a significant role in mitigating oxidative stress.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CAT (Catalase)
    |
    chlorogenic acid
    16d
    Phase Ia/Ib Study of RS-0139 in Patients with a Recurrent, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=16, Recruiting, RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. | Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Oct 2025
    Trial completion date • Trial primary completion date • Metastases
    17d
    Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis) (clinicaltrials.gov)
    P3, N=200, Not yet recruiting, University Hospital, Strasbourg, France
    New P3 trial
    18d
    Role of L-citrulline in Prevention of Pregnancy Associated Hypertension (clinicaltrials.gov)
    P1, N=338, Suspended, The University of Texas Medical Branch, Galveston | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    18d
    Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, Annexin Pharmaceuticals AB | Trial completion date: Jul 2024 --> Nov 2024
    Trial completion date
    |
    ANXA5 (Annexin A5)
    19d
    Hydroxychloroquine inhibits the growth of lung cancer cells by inducing G1 cell cycle arrest and apoptosis. (PubMed, Pak J Pharm Sci)
    The findings from this study offered robust evidence supporting the use of hydroxychloroquine as a treatment for non-small cell lung cancer (NSCLC). Consequently, hydroxychloroquine emerges as a potential therapeutic agent for the treatment of this cancer.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    hydroxychloroquine
    19d
    Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols. (PubMed, Pharmaceuticals (Basel))
    Some polyphenols can reverse part of the liver damage related to inflammation, oxidative stress, or mitochondrial dysfunction, and among them are anthocyanin, baicalin, catechin, curcumin, chlorogenic acid, didymin, epigallocatechin-3-gallate, luteolin, mangiferin, puerarin, punicalagin, resveratrol, and silymarin...On the other hand, they can improve HDL-c, adiponectin levels, and fibrogenesis markers. These results show that polyphenols are promising in the prevention and treatment of MAFLD.
    Review • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1)
    |
    chlorogenic acid
    21d
    Exploring the anticancer potential of Lasia spinosa rhizomes: insights from molecular docking and DFT investigations on chlorogenic acid and beyond. (PubMed, Nat Prod Res)
    Additionally, density functional theory studies indicated the strong electrophilic nature of CA and its potential for robust enzyme binding interactions. Subsequent MTT assays focusing on CA exhibited significant activity against all tested cell lines, with IC50 values ranging from 21.56 to 72.60 μg/ml, comparable to quercetin.
    Journal
    |
    KDR (Kinase insert domain receptor) • TOP2A (DNA topoisomerase 2-alpha) • CDK2 (Cyclin-dependent kinase 2)
    |
    chlorogenic acid
    23d
    CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma (clinicaltrials.gov)
    P2, N=44, Terminated, Regeneron Pharmaceuticals | Completed --> Terminated; Business Decision
    Trial termination • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Opdivo (nivolumab) • vidutolimod (CMP-001)
    23d
    CMP-001-011: CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma (clinicaltrials.gov)
    P2/3, N=20, Terminated, Regeneron Pharmaceuticals | Completed --> Terminated; Business Decision
    Trial termination • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • vidutolimod (CMP-001)
    23d
    CMP-001-007: CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=24, Terminated, Regeneron Pharmaceuticals | Completed --> Terminated; Business Decision
    Trial termination • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • vidutolimod (CMP-001)
    24d
    QT-LIFE: Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab (clinicaltrials.gov)
    P=N/A, N=796, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New trial
    |
    hydroxychloroquine
    25d
    Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab (clinicaltrials.gov)
    P2, N=9, Completed, Diwakar Davar | Active, not recruiting --> Completed | Trial completion date: Jul 2028 --> Aug 2024 | Trial primary completion date: Jul 2028 --> Aug 2024
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD8 (cluster of differentiation 8)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • vidutolimod (CMP-001)
    25d
    A Safety and Efficacy Study of PVX108 in Children and Adolescents with Peanut Allergy (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Aravax Pty Ltd | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    28d
    LDN-CRPS: Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome (clinicaltrials.gov)
    P4, N=40, Enrolling by invitation, Hospital for Special Surgery, New York | Recruiting --> Enrolling by invitation
    Enrollment status
    29d
    Acclaim-1: Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (clinicaltrials.gov)
    P1/2, N=158, Recruiting, Genprex, Inc. | Trial completion date: Dec 2027 --> Mar 2029 | Trial primary completion date: Dec 2026 --> Mar 2028
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • Reqorsa (quaratusugene ozeplasmid)
    30d
    NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=20, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Jun 2026 --> Oct 2026
    Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)
    1m
    Islet Transplantation Using PKX-001 (clinicaltrials.gov)
    P1, N=6, Recruiting, University of Alberta | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
    Trial completion date • Trial primary completion date